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Returning Genetic Research Results: 
Considerations for Existing No-Return 
and Future Biobanks 
Karen J. Maschke* 
 I. INTRODUCTION 
A pressing issue for the genetic research enterprise—and 
an issue that has important implications for biobanks—is 
whether researchers should share, or “return,” the genetic re-
search results with the individuals whose DNA they studied.1 
With some exceptions, researchers typically have not returned 
genetic research results to the biospecimen donors.2 One reason 
for a no-return policy is that researchers typically study DNA 
samples that have been stripped of personal identifiers, making 
it difficult or impossible to link information about specific sam-
ples to their donors.3 Even if individuals can be re-identified, 
most genetic research results have uncertain clinical signifi-
cance.4 Nonetheless, some commentators—including prospec-
                                                          
© 2012 Karen J. Maschke 
 *  The author would like to thank Laura Beskow for insightful comments 
related to consent issues and to Steve Thibodeau for guidance about results 
policies at institutions with multiple biobanks. Preparation of this article was 
supported by the National Institutes of Health (NIH), National Human Ge-
nome Research Institute (NHGRI) grant #2-R01-HG003178 on “Managing In-
cidental Findings and Research Results in Genomic Biobanks & Archives” 
(Wolf, PI; Kahn, Lawrenz, Van Ness, Co-Is). The contents of this article are 
solely the responsibility of the author(s) and do not necessarily represent the 
views of NIH or NHGRI. 
 1. Susan M. Wolf et al., Managing Research Results and Incidental Find-
ings in Genomic Research Involving Biobanks & Archived Datasets, 14 
GENETICS MED. 361 (2012). 
 2. See Christopher Heaney et al., Researcher Practices on Returning Ge-
netic Research Results, 14 GENETIC TESTING AND MOLECULAR BIOMARKERS 
821, 821 (2010) (reporting that twenty-four percent of surveyed authors of ge-
netic or genomic studies returned results). 
 3. Wolf et al., supra note 1, at 369. 
 4. See id. at 368 (raising the concern that research participants might 
“mistake research for clinical care” and the process “may involve return of 
findings that are not adequately understood and validated”). 
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tive and actual biospecimen donors—contend that donors 
should have acesss to their own genetic information, even if its 
clinical significance is uncertain.5 As evidence emerges that 
some genetic information does have clinical significance, a con-
sensus is emerging among a wide range of stakeholders for a 
conditional-return approach, which would entail returning 
some results to biospecimen donors.6 
A recent set of recommendations by Wolf et al., for a condi-
tional-return approach is directed specifically to biobanks. 
Biobanks are resources for scientific research, containing hu-
man biospecimens such as blood, saliva, and tissue samples—
healthy and diseased—from surgical and diagnostic proce-
dures.7 Many biobanks also contain personal health infor-
mation about the biospecimen donors and the data researchers 
derive from their studies.8 Although not new, “[b]iobanks have 
become crucial to the conduct of genetic and genomic research, 
especially large-scale genomic research.”9 Biobanks provide re-
searchers with ready access to biospecimens and data, thus de-
                                                          
 5. Erin D. Harris et al., The Beliefs, Motivations, and Expectations of 
Parents Who Have Enrolled their Children in a Genetic Biorepository, 14 
GENETICS IN MED. 330, passim (2012); Daniel MacArthur, When “Cautious” 
Means “Useless,” WIRED SCI. BLOG (Feb. 18, 2011, 12:17 PM), 
http://www.wired.com/wiredscience/2011/02/when-cautious-means-useless/ 
(arguing that information should be returned to participants even if it is not 
“actionable”). 
 6. See Ebony Bookman et al., Reporting Genetic Results in Research 
Studies: Summary and Recommendations of an NHLBI Working Group, 140A 
AM. J. MED. GENETICS 1033, 1033 (2006) (concluding that results should only 
be returned to participants if the “associated risk for disease is significant”); 
Richard R. Fabsitz et al., Ethical and Practical Guidelines for Reporting Ge-
netic Research Results to Study Participants, 3 CIRCULATION: 
CARDIOVASCULAR GENETICS 574, 575 (2010) (offering a list of conditions that, 
if satisfied, would warrant the return of research results); Vardit Ravitsky & 
Benjamin S. Wilfond, Disclosing Individual Genetic Results to Research Partic-
ipants, 6 AM. J. BIOETHICS 8, 8 (2006) (“The ethical principles of beneficence, 
respect, reciprocity, and justice provide justification for routinely offering cer-
tain results to research participants.”); Wolf, supra note 1, at 378 (stating that 
some findings should be offered back to the contributor); Susan M. Wolf et al., 
Managing Incidental Findings in Human Subjects Research: Analysis and 
Recommendations, 36 J. L. MED & ETHICS 219, 230 tbl.3 (2008) [hereinafter 
Wolf II] (comparing recommendations as to when individual research results 
should be returned to the participant). 
 7. See Wolf et al., supra note 1, at 361. 
 8. See id. at 363 (“A biobank is a structured resource that holds human 
biological samples and/or data to facilitate research over time.”). 
 9. Id. 
005 MASCHKE_PROOF -SK.DOCX (DO NOT DELETE) 7/5/2012  1:14 PM 
2012] RETURNING GENETIC RESEARCH RESULTS 561 
creasing the time and expense of collecting those materials on 
their own.10 Because biobanks are a central part of a “biobank 
research system,” Wolf et al. argue that they shoulder 
signficiant responsibilities for managing the return of genetic 
research results to biospecimen donors.11 
The ethical justifications for returning genetic research re-
sults and the criteria suggested for determining when results 
are returnable are beyond the scope of this paper. Rather, this 
paper will identify several ethical and practical issues that ex-
isting biobanks with a no-return policy, and future biobanks, 
will have to consider in determining whether and how to return 
genetic research results to biospecimen donors. These issues 
involve the consent status of biospecimens and data, the 
“identifiability” of those materials, the analytical validity of ge-
netic research results, and the disclosure process. Finally, this 
paper suggests that at medical institutions with multiple condi-
tional-return biobanks, decision-making regarding the criteria 
for what results are returnable should take place at the institu-
tional level, rather than at the level of individual biobanks. 
II. GENETIC RESEARCH RESULTS: EXISTING NO-
RETURN AND FUTURE BIOBANKS 
Biobanks have three options for managing genetic research 
results: 1) never share results with the individuals whose DNA 
was analyzed (no-return approach); 2) return some results to 
some individuals (conditional-return approach); or 3) return all 
of the genetic information generated by the DNA analysis to 
the individual donors (always-return approach). The limited 
empirical data regarding biobanks in the U.S. suggest that 
most biobanks use the no-return approach.12 The known excep-
tions are several new large-scale biobanks that use the condi-
                                                          
 10. See PANEL ON COLLECTING, STORING, ACCESSING, AND PROT. 
BIOLOGICAL SPECIMENS AND BIODATA IN SOC. SURVEYS ET AL., CONDUCTING 
BIOSOCIAL SURVEYS 41 (2010) (“One of the advantages of collecting biological 
specimens as part of social surveys is that digital representations of the data 
derived from the specimens . . . can be appended to the survey data and shared 
with other researchers. Wide dissemination of data facilitates advances in re-
search and public policy”). 
 11. Wolf et al., supra note 1, at 362. 
 12. See Gina M. Johnson et al., Special Article, An Empirical Examination 
of the Management of Return of Individual Research Results and Incidental 
Findings in Genomic Biobanks, GENETICS MED., 1, 6 (2012), 
http://www.nature.com/gim/journal/vaop/ncurrent/pdf/gim201220a.pdf (ad-
vance online publication). 
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tional-return approach.13 At least one biobank, the Personal 
Genome Project, comes closest to meeting the definition of an 
always-return approach where participants are given all genet-
ic information derived from the research analysis of their 
biospecimen.14 
A. IDENTIFIABILITY AND CONSENT ISSUES 
Given the compelling ethical justifications for returning 
genetic research results having clinical significance,15 a thresh-
old question for future biobanks is whether they should be de-
signed so that no results are ever returned to individual 
biospecimen donors. Some may suggest the answer is yes, even 
if there is a possibility that some research results will have 
clinical significance. At least one new biobank, Vanderbilt Uni-
versity’s BioVU, irreversibly de-identifies the DNA samples 
and data it collects, meaning that genetic research results can 
never be returned to the biospecimen donors.16 
For an existing no-return biobank, the identifiability issue 
raises at least two scenarios. If the biobank irreversibly de-
identifies biospecimens and data, it can never return genetic 
research results to the biospecimen donors. However, if the 
biobank is still collecting biospecimens and data, it could apply 
the conditional- or always-return approach to the newly collect-
ed materials. This scenario raises the question of whether an 
                                                          
 13. See, e.g., Leslie G. Biesecker et al., The ClinSeq Project: Piloting 
Large-Scale Genome Sequencing for Research in Genomic Medicine, 19 
GENOME RES. 1665, 1667 (2009) (informing participants that they will be con-
tacted “to determine if they are interested in learning about clinically relevant 
results”); Frequently Asked Questions, CORIELL, http://cpmc.coriell.org/Sec 
tions/About/FAQs.aspx?PgId=13 (last visited Jan. 29, 2012) (stating that par-
ticipants will not be informed of results for which there is not treatment or in-
tervention available for treating the disease); Informed Cohort, The Gene 
Partnership, CHILD. HOSP. BOSTON, http://www.genepartnership.org/about-
tgp/informed-cohort/ (last visited Jan. 29, 2012) (research subjects are part of 
an “informed cohort,” participating as “partners in their own research”). 
 14. See How it Works, PERS. GENOME PROJECT, http://www.personalgen 
omes.org/howitworks.html (last updated Apr. 1, 2011) (“Once the PGP has 
completed the analysis of your specimen(s), the PGP will make the data avail-
able to you”). 
 15. See Wolf et al., supra note 1, at 367–68 (discussing ethical concerns 
surrounding return of research findings). 
 16. Jill Pulley et al., Principles of Human Subjects Protections Applied in 
an Opt-Out, De-identified Biobank, 3 CLINICAL & TRANSLATIONAL SCI. 42, 42 
(2010). 
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existing no-return biobank that irreversibly de-identifies 
biospecimens and data should change this approach so that 
some, if not all, results can be returned to new biospecimen do-
nors. Or like a new biobank that irreversibly de-identifies 
biospecimens and data so that genetic results can never be re-
turned to biospecimen donors, is it ethically justifiable for an 
existing no-return biobank to continue that approach? 
Even if an existing no-return biobank can link genetic re-
sults to a specific individual’s DNA sample, several consent-
related issues must be addressed to move from a no-return to a 
conditional- or always-return approach.17 For example, were 
the biospecimens and data obtained with consent from individ-
ual donors for use in research, including genetic research? 
What if the no-return identifiable biobank holds residual 
biospecimens derived from surgical and diagnostic procedures 
that are linked to personal identifiers but that were obtained 
without consent for research? What if the biobank holds identi-
fiable materials collected with consent for specific research, but 
the materials were not irreversibly de-identified and used for 
different research? 
Anecdotal reports suggest that many medical research in-
stitutions control biobanks containing biospecimens that were 
obtained without consent for research or whose consent status 
is uncertain.18 Yet some individuals might be upset to learn 
that their DNA was used in research without their consent or 
may not welcome a biobank contacting them regarding the ge-
netic information researchers discovered.19 Alternatively, what 
if genetic research results have clinical significance in the sense 
that preventive or treatment approaches are available? Does a 
biobank have a duty to offer clinically significant results to in-
dividuals if they did not know their biospecimens were kept 
                                                          
 17. See generally Wolf II, supra note 6, at 227 (“[R]esearchers have an ob-
ligation to address the possibility of discovering IFs not only in their protocol 
and communications with the IRB, but also in their consent forms and com-
munications with those being recruited to the study and research partici-
pants”). 
 18. See ROBERT F. WEIR & ROBERT S. OLICK, THE STORED TISSUE ISSUE: 
BIOMEDICAL RESEARCH, ETHICS, AND LAW IN THE ERA OF GENOMIC MEDICINE 
26 (2004) (“Tissue has frequently been collected without appropriate disclosure 
to patients and research participants about why tissues are needed for re-
search purposes and what investigators plan or hope to do with them”). 
 19. See, e.g., Ellen Wright Clayton, Incidental Findings in Genetics Re-
search Using Archived DNA, 36 J.L. MED. & ETHICS 286, 290 (2008) (stating 
that research participants want to receive incidental findings, but the way 
that information is disclosed is important). 
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and used for research and if the consent form was silent or 
vague about returning results?20 
For existing no-return biobanks that collected 
biospecimens and data from individuals who gave consent for 
their use in research, the first step is to determine what, if any-
thing, the consent form says about research results. Does the 
consent form explicitly state that no genetic results will be re-
turned, is it silent on the issue of returning results, or does it 
mention results but contain vague language about the matter? 
A recent empirical study of publicly available documents from 
selected biobanks in the United States found that less than half 
addressed the issue of returning research results in some man-
ner.21 
Regardless of whether the consent form for an existing no-
return biobank says anything about research results, does it 
explain whether the biobank will or may re-contact 
biospecimen contributors? If re-contact is mentioned, does the 
consent form give individuals the opportunity to decline to be 
re-contacted, or is being re-contacted a condition of enrolling in 
the biobank? One option is to maintain the no-return policy for 
the biospecimens and data already in the biobank, but use the 
conditional-return approach with future biospecimen donors 
who are informed about the new policy for returning genetic re-
search results. 
Another consent issue that has yet to be fully addressed in 
the return-of-results literature involves genetic research re-
sults generated after a biospecimen contributor has died. 
Should genetic information be shared with the decedent’s rela-
tives?22 No empirical data is available documenting how 
biobanks address this issue, although the publicly-available 
consent forms of two new large-scale conditional-return ap-
                                                          
 20. See Laura Beskow & Wylie Burke, Offering Individual Genetic Re-
search Results: Context Matters, 2 SCI. TRANSLATIONAL MED. 1, 4 tbl.1 (2010) 
(comparing different obligations to share information based on the research 
context). 
 21. Johnson et al., supra note 12, at 4 (noting that seven (sixteen percent) 
of the forty-three biobanks surveyed returned information to participants 
while fourteen (thirty-three percent) did not). 
 22. See Anne Marie Tassé, Biobanking and Deceased Persons, 130 HUM. 
GENETICS 415, 419 (2011) (discussing the considerations that must be ad-
dressed when making the determination to return genetic results to the family 
members of deceased donors). 
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proach biobanks indicates that they do not do so.23 
Some commentators may argue that a consent form is not a 
contract in the sense that omissions in the document regarding 
matters such as re-contacting research participants or offering 
them research results from analyses of their DNA mean that 
such activities are prohibited. However, as noted above, others 
contend that contacting individuals who are unaware that their 
DNA was used in research raises several concerns.24 Little em-
pirical data are available regarding IRB members’ perspectives 
about consent issues related to the return of genetic results. 
However, several studies indicate that with regard to other 
consent-related matters, IRB members have differing opinions 
about when reconsent is ethically necessary.25 
As to the issue of returning genetic research results to the 
relatives of decedents, state and federal privacy laws may pro-
hibit the disclosure of genetic information without consent from 
the individual whose information is at issue.26 Future biobanks 
using a conditional-return approach may consider asking 
biospecimen donors whether they want the biobank to share 
genetic research results with their relatives if the results are 
obtained post-mortem. Existing no-return biobanks still collect-
ing biospecimens that ultimately adopt the conditional-return 
approach could do the same. For an existing conditional-return 
                                                          
 23. See, e.g., CORIELL PERS. MED. COLLABORATIVE, CONSENT TO 
PARTICIPATE IN A RESEARCH STUDY (Nov. 13, 2008), available at 
http://cpmc.coriell.org/Docs/PDF/Informed_Consent.pdf; see also MAYO CLINIC, 
CONSENT FORM (Oct. 6, 2010), available at http://mayoresearch.mayo.edu 
/biobank/upload/biobank-consent-viewable.pdf. 
 24. See generally Clayton, supra note 19, at 287 (stating that some pa-
tients, like those at research hospitals, have no idea that their samples might 
be used for current or future research and even those who know that their 
samples will be used don’t know to what extent). 
 25. See, e.g., Karen L. Edwards et al., Genetics Researchers’ and IRB Pro-
fessionals’ Attitudes Toward Genetic Research Review: A Comparative Analysis 
14 GENETICS MED. 236, 240 (2012) (“Both [genetic researchers and IRB staff] 
displayed a range of opinions on most questions.”); Amy A. Lemke et al., Atti-
tudes Toward Genetic Research Review; Results From a National Survey of 
Professionals Involved in Human Subjects Protection, 5 J. EMPIRICAL RES. 
HUM. RES. ETHICS 83 passim (2010); see also Leslie E. Wolf et al., IRB Chairs’ 
Perspectives on Genomics Research Involving Stored Biological Materials: Eth-
ical Concerns and Proposed Solutions 3 J. EMPIRICAL RES. HUM. RES. ETHICS 
99, 106–09 (2008) (describing results of a survey of IRB Chairs that posed hy-
pothetical questions regarding mental health-related genomics research and 
using stored specimens to perform research). 
 26. WEIR & OLICK, supra note 18, at 139 (“The federal policy makes duties 
of confidentiality clear, but is largely deferential to state law and local practice 
regarding the rules and methods for meeting this obligation.”). 
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biobank whose consent form is silent on the issue, it is unclear 
whether the biobank has an ethical “duty to warn” relatives 
about genetic information that might have clinical significance 
for them.27 How IRBs will respond if a biobank wants to offer 
genetic results to a deceased donor’s relatives remains to be 
seen 
B. THE CLIA ISSUE 
If existing no-return and future biobanks decide to return 
some genetic research results to study participants, they must 
also decide whether to return only results that were generated 
in a laboratory complying with the certification requirements of 
the Clinical Laboratory Amendments of 1988 (CLIA).28 CLIA 
and accompanying regulations require laboratories that report 
“patient specific results for the diagnosis, prevention or treat-
ment of any disease or impairment of, or the assessment of the 
health of individual patients” to be CLIA certified.29 Since re-
search laboratories do not report results to clinicians, most are 
not CLIA certified. Nonetheless, several conditional-return 
biobanks offer only CLIA-validated results to participants.30 
Commentators disagree about how to interpret CLIA re-
quirements in the research context. According to Roberts et al., 
if the original genetic testing was not conducted in a CLIA-
certified laboratory and “the decision to communicate research 
results is because of their potential clinical significance, retest-
ing should occur in a CLIA-certified laboratory.”31 But they 
                                                          
 27. See Beskow & Burke, supra note 20, at 1–2 (suggesting that research-
ers may have an ethical “duty to rescue” when “an investigator discovers ge-
netic information that clearly indicates a high probability of a serious condi-
tion for which an effective intervention is readily available”); Marni J. Falk et 
al., Medical Geneticists’ Duty to Warn At-Risk Relatives for Genetic Disease, 
120A AM. J. MED. GENETICS 374, 375 (2003) (stating the alternative positions 
of putting the responsibility on the researcher to disclose versus leaving that 
responsibility to the individual having the testing). 
 28. 42 U.S.C. § 263a (2006); 42 C.F.R. §§ 493.1–493.2001 (2011). 
 29. 42 C.F.R. § 493.3(b)(2) (2011). 
 30. See, e.g., ClinSeq: A Large-Scale Medical Sequencing Clinical Re-
search Pilot Study, GENOME.GOV, http://www.genome.gov/25521306 (last re-
viewed Nov. 17, 2010); Frequently Asked Questions, CORIELL PERSONALIZED 
MED. COLLABORATIVE, http://cpmc.coriell.org/sections/about/faqs.aspx?pgid=13 
(last visited Jan. 30, 2012). 
 31. J. Scott Roberts et al., Returning Individual Research Results: Devel-
opment of a Cancer Genetics Education and Risk Communication Protocol, 5 J. 
EMPIRICAL RES. ON HUM. RES. ETHICS 17, 20 (2010). 
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contend that if the genetic results “are communicated because 
of non-clinical value, such as personal meaning (or because re-
sponse to research results was what was being assessed in the 
study), CLIA certification is not necessarily required.”32 The 
consent form for the Roberts study explained that the tests 
would not be conducted in a CLIA-certified laboratory and that 
participants could have their results CLIA validated at their 
own expense.33 Some institutions may require genetic research 
results to be CLIA-validated before they are offered to 
biospecimen donors. Yet in a study of IRB chairs’ perspectives 
about returning genetic research results, two examples were 
described in which an IRB overruled its own guidance that only 
results obtained in a CLIA-certified laboratory could be re-
turned to research participants.34 Although some representa-
tives from the Centers for Medicare & Medicaid Services 
(“CMS”)—the federal agency that enforces CLIA—have stated 
that “test results returned to individuals are always considered 
subject to CLIA,”35 it remains unclear how CMS will respond if 
biobanks (or individual researchers) return genetic research re-
sults to biospecimen contributors that were not obtained in a 
CLIA-certified laboratory. 
C. DISCLOSURE CONSIDERATIONS 
Another important consideration for existing no-return and 
future biobanks that decide to adopt the conditional- or always-
return approach is how to manage the disclosure process. De-
spite claims that genetic information is not exceptional vis-a-vis 
other medical information—such as results from blood tests or 
x-rays—36genetic information is often treated exceptionally. 
Indeed, specialized genetic counselors often help individu-
                                                          
 32. Id. 
 33. Id. at 20–21. 
 34. Lynn G. Dressler et al., IRB Perspectives on the Return of Individual 
Results from Genomic Research, 14 GENETICS MED. 215, 217 (2012). 
 35. Penelope Meyers, CLIA and Research Results, CENTERS FOR 
MEDICARE AND MEDICAID SERVICES (Mar. 28, 2011), http://www.hhs.gov/ohrp/ 
sachrp/mtgings/mtg03-11/rirr_by_p_meyers.pdf. 
 36. Thomas H. Murray, Genetic Exceptionalism and “Future Diaries”: Is 
Genetic Information Different from Other Medical Information?, in GENETIC 
SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY IN THE GENETIC ERA 
60, 61 (Mark A. Rothstein ed.,1977) ( defining genetic exceptionalism “to mean 
roughly the claim that genetic information is sufficiently different from other 
kinds of health-related information that deserves special protection” and stat-
ing that genes are “uniquely personal” and thus require that protection). 
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als interpret and understand their genetic test information, a 
practice unique to genetic research.37 If biobanks adopt the 
conditional- or always-return approach, should they require in-
dividuals to obtain the results from a genetic counselor and un-
dergo formal genetic counseling? If a biobank requires genetic 
counseling as a condition of receiving genetic research results, 
who pays for the counseling? Even if genetic counseling is not 
required, should results be disclosed by a genetic counselor or 
by the donors’ physician? Does disclosure of results have to in-
volve personal interaction or may results be disclosed by mail, 
telephone, or through electronic forms of communication? Some 
parents whose children are participating in biobank research 
say they prefer to receive their child’s results electronically,38 
and adult biobank participants may be open to receiving their 
results by telephone, regular mail, or e-mail.39 The Coriell Per-
sonalized Medicine Collaborative and the Gene Partnership are 
integrating innovative web-based portals and personal health 
records platforms into their disclosure process.40 These disclo-
sure approaches diverge from standard approaches involving 
one or more face-to-face meetings with a genetic counselor to 
receive genetic test information, and raise issues about a 
biobank’s capacity to develop and implement innovative disclo-
sure strategies. 
D. INFRASTRUCTURE AND CAPACITY 
Shifting the focus from the individuals whose DNA re-
searchers analyze to the researchers themselves implicates an-
other set of considerations. For instance, an existing no-return 
biobank that changes to a conditional- or always-return ap-
proach will need to consider whether the new policy will affect 
researchers who have already received biospecimens and data 
from the biobank, or only researchers who receive materials af-
ter a certain date. Biobanks will also need to inform research-
                                                          
 37. See Frequently Asked Questions, MAYO CLINIC, 
http://www.mayoclinic.org/genetic-counseling-sct/faq.html (last visited Feb. 17, 
2012). 
 38. Harris et al., supra note 5. 
 39. See, e.g., David I. Shalowitz & Frank G. Miller, Communicating the 
Results of Clinical Research to Participants: Attitudes, Practices and Future 
Directions, 5 PLoS MED. 714, 718–19 (2008) (“[P]articipants often prefer to re-
ceive results in writing with contact information.”). 
 40. See Frequently Asked Questions, supra note 13. 
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ers about what results will or may be offered to individuals, 
what they are to do with such results, and how the disclosure 
process works. Biobanks could consider using material transfer 
and data access agreements to stipulate the conditions under 
which researchers should report results to the biobank that will 
or may be returned to individuals. However, researchers typi-
cally are prohibited by material transfer and data use agree-
ments from re-identifying or contacting the individuals whose 
materials they received and used in their studies. 
All of the considerations discussed above raise an issue 
about the capacity—defined broadly—of an existing no-return 
biobank or future biobank to adopt a conditional- or always- re-
turn approach. A broad definition of capacity includes a range 
of considerations about personnel, biospecimen and data track-
ing, information technology (IT), requirements for review and 
approval of a return approach by the IRB and/or other over-
sight committees, CLIA testing, and the specifics of the disclo-
sure process.41 All of these considerations translate into addi-
tional costs for an existing no-return biobank, as well as for 
future biobanks. From a normative perspective, should cost is-
sues regarding capacity be determinative for existing no-return 
biobanks and for future biobanks? 
III. RETURNABLE RESULTS: WHO DECIDES? 
A key question that arises when adopting the conditional-
return approach is who should decide what results are return-
able? Some commentators have suggested that biobanks could 
establish a specialized committee separate from the IRB to be 
the decision-maker, and several new biobanks—the Coriell 
Personalized Medicine Collaborative, the Gene Partnership at 
Boston Children’s Hospital, and the Mayo Clinic Biobank—
have adopted this approach. The committee at the Coriell Per-
sonalized Medicine Collaborative is the Informed Consent 
                                                          
 41. Marianna J. Bledsoe et al., Practical Implementation of Issues and 
Challenges for Biobanks in the Return of Individual Research Results, 
GENETICS MED. 1, 2–3 (2012), http://www.nature.com/gim/journal/vaop 
/ncurrent/pdf/gim201167a.pdf (noting that biobanks will have to consider a 
host of practical issues if they decide to return results to individual donors) 
(advance online publication); Michael Ferriere & Brian Van Ness, Return of 
Individual Research  Results and Incidental Findings in the Clinical Trials 
Cooperative Group Setting,  GENETICS MED.  1, 6 (2012), http://www.nature. 
com/gim/journal/vaop/ncurrent/pdf/gim201214a.pdf (advance online publica-
tion); Wolf et al., supra note 1. 
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Oversight Board (ICOB).42 The Gene Partnership created the 
Informed Cohort Oversight Board (ICOB) and the Mayo Clinic 
Biobank created the Biospecimen Trust Oversight Group 
(BTOG).43 The IRBs that approved the protocols for these 
biobanks did so with the understanding that the biobanks 
would create a specialized committee to determine what results 
to return to biospecimen donors. 
Yet left unadressed in the literature on the return of re-
sults is who the decision-maker should be at medical institu-
tions that have multiple conditional-return biobanks. Anecdotal 
evidence suggests that many medical institutions have multiple 
biobanks—ranging from small collections of healthy and dis-
eased tissue to collections like the Mayo Clinic Biobank that 
hold thousands of specimens.44 Medical institutions with mul-
tiple conditional-return biobanks should consider developing an 
institutional return of results committee separate from the IRB 
to establish criteria for returnable results and to assist 
biobanks in determining when research findings meet those 
criteria. 
One reason for an institutional return of results committee 
is to promote fair access to genetic research results. For in-
stance, what if one biobank at an institution decides it will in-
form donors if they have the Apoe4 genotype, but another 
biobank at the same institution will not? Why should some 
biospecimen donors have access to that information, but not 
others? A further reason for an institutional return of results 
committee is that some results, like those that reveal gene var-
iants related to drug metabolism, may be clinically actionable. 
It seems reasonable to suggest that institutions with multiple 
conditional-return biobanks should have a uniform approach to 
                                                          
 42. See Frequently Asked Questions, supra note 13. 
 43. See Governing the Biobank, MAYO CLINIC, 
http://mayoresearch.mayo.edu/biobank/biobank-governing.cfm (last visited 
Feb. 16, 2012); History, CHILDREN’S HOSP. BOSTON (Oct. 16, 2010), 
http:www.genepartnership.org/about-tgp/history/. 
 44. The director of the Mayo Clinic Biobank estimates there may be hun-
dreds of collections of biospecimens at the Mayo Clinic that meet the definition 
of a biobank. Email from Stephen N. Thibodeau, Director of the Mayo Clinic 
Biobank, to Karen Maschke, Research Scholar, The Hastings Center (August 
14, 2011) (on file with author).  As of the end of 2011, the Biobank had 22,499 
participants. BioNews: Fall/Winter 2011, The Mayo Clinic Biobank, 
http://www.mayo.edu/pmts/mc6200-mc6299/mc6276-1111.pdf (last visited 
March 30, 2012). 
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establishing the criteria for results that are clinically actiona-
ble so that all biospecimen donors will have access to results 
that have implications for their clinical care. 
Some will object to creating yet another institutional com-
mittee and placing decision-making in such a committee rather 
with the IRB. Yet it is not self-evident that the IRB is the ap-
propriate committee to establish the criteria for returnable re-
sults and to assist biobanks in determining when those criteria 
are met with regard to specific genetic findings. Many commen-
tators claim that IRBs are unnecessarily overburdened with 
regulatory responsibilities regarding the protection of research 
participants.45 Moreover, some commentators complain about 
IRB “mission creep,” that is, assuming responsibility for mat-
ters beyond specific regulatory domains.46 
The Coriell Personalized Medicine Collaborative, the Gene 
Partnership and the Mayo Clinic Biobank have established a 
precedent for a return of results committee at the biobank lev-
el, and there is evidence that some commentators and IRB 
members are attracted to such a decision-making body separate 
from the IRB. For instance, at a workshop the National Cancer 
Institute convened in 2010 to address the issue of biospecimen 
donors’ research results, participants expressed varying opin-
ions about whether the IRB should assume the role of institu-
tional decision-maker about what results are returnable. One of 
the breakout groups “agreed that the IRB should review and 
approve proposed mechanisms for the return of research re-
sults” and that “when a potentially returnable research result 
arises, the investigator should notify the IRB and seek guid-
ance on whether the result should be returned.”47 This 
breakout group also recommended that a “smart filter” be cre-
                                                          
 45. Norman Fost & Robert J. Levine, Editorial, The Dysregulation of Hu-
man Subjects Research, 298 J. AM. MED. ASS’N 2196, 2196 (2007); Scott Kim et 
al., Commentary, Pruning the Regulatory Tree, 457 NATURE 534, 534 (2009) 
(stating that all minimal-risk research should be deregulated). 
 46. C. K. Gunsalus et al., Improving the System for Protecting Human 
Subjects: Counteracting IRB “Mission Creep” passim (Ctr. for Advanced Study, 
The Illinois White Paper May 18, 2006), available at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=902995 (select “One-click 
Download”). 
 47. Workshop on Release of Research Results to Participants in 
Biospecimen Studies: Workshop Summary (Office of Biorepositories & 
Biospecimen Research, Nat’l Cancer Inst. & Nat’l Inst. Health, Mar. 4, 2011), 
available at 
http://biospecimens.cancer.gov/global/pdfs/NCI_Return_Research_Results_Su
mmary_Final-508.pdf. 
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ated, i.e., a list of criteria regarding what results are returna-
ble, and that the IRB should use the filter “to evaluate the va-
lidity of the results and determine whether the results should 
be returned.”48 Although this breakout group also said the “IRB 
may seek guidance from an advisory committee that includes 
members with expertise in the techniques used by the re-
search,” it is unclear whether the group meant that the adviso-
ry committee, and not the IRB, should make the final determi-
nation about what results are returnable.49 
Yet, as previously noted, missing from the commentary 
about biobanks establishing criteria for returnable results is 
the recognition that many medical institutions likely have mul-
tiple biobanks that already return some results to donors or 
that may shift from a no-return to a conditional-return ap-
proach. The Coriell, Gene Partnership, and Mayo models in-
clude members with expertise in genetics, medicine, and bio-
ethics. The committees for those biobanks also include 
community members from the general public. 
In addition to the precedent established by the Coriell Per-
sonalized Medicine Collaborative, the Gene Partnership, and 
the Mayo Clinic Biobank, there is additional precedent for in-
stitutional-level committees that are parallel to and work in 
tandem with the IRB. For instance, some institutions have an 
institutional conflict of interest committee that establishes fi-
nancial and other disclosure requirements for researchers, in-
cluding what information to disclose to the IRB at the protocol 
review stage.50 And many institutions have separate oversight 
committees that review protocols for embryonic stem cell re-
search.51 Finally, several institutional members of the NIH’s 
Clinical and Translational Science Awards program have de-
veloped a research ethics consultation service that comple-
ments, but is separate from, the IRB.52 
                                                          
 48. Id. at 35. 
 49. Id. at 36. 
 50. Michael Camilleri, Principles and Process in the Development of the 
Mayo Clinic’s Individual and Institutional Conflict of Interest Policy, 80 MAYO 
CLINIC PROC. 1340 (2005). 
 51. NAT’L RES. COUNCIL & INST. MED. NAT’L ACADS., 2007 AMENDMENTS: 
THE NATIONAL ACADEMIES’ GUIDELINES FOR HUMAN EMBRYONIC STEM CELL 
RESEARCH 10–11 (2007). 
 52. See Mildred K. Cho et al., Strangers at the Benchside: Research Ethics 
Consultation 8 AM. J. BIOETHICS 4, 6 (2008). 
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IV. CONCLUSION 
In recent years, several groups and individual commenta-
tors have made a compelling case that researchers and 
biobanks have an ethical obligation to return some, if not all, 
genetic research results to the individuals whose DNA re-
searchers studied.53 These calls for a conditional-return ap-
proach raise a host of ethical and practical considerations for 
existing no-return biobanks, as well as for future biobanks. No-
return biobanks that can link genetic results to a specific do-
nor’s DNA sample will need to consider whether the ethical ar-
guments in favor of the conditional-return approach compel 
them to change their policy. Future biobanks will have to de-
cide whether it is ethically justifiable to irreversibly de-identify 
biospecimens, since doing so means that genetic results can 
never be returned to donors. 
Shifting from a no-return to a conditional-return approach 
implicates issues that IRBs will have to address regarding the 
original consent of biospecimen donors and the disclosure pro-
cess. Adding to the complexity of the issue regarding the condi-
tional-return approach is that many biobanks in the U.S. are 
located in medical institutions that have multiple biobanks.54  
The proposal here is for an institutional return of results com-
mittee to establish the criteria for returnable results shifts de-
cision-making away from individual biobanks and the IRB, and 
creates the opportunity for consistent and fair policies across 
all of an institution’s conditional-return biobanks. 
 
                                                          
 53. See e.g., Bookman et al., supra note 6; Fabsitz et al., supra note; Wolf 
et al., supra note 1; Wolf II, supra note 6. 
 54. See, e.g., Powering the Next Wave of Medicine, CHILDREN’S HOSP. 
BOSTON, http://www.genepartnership.org/ (last visited Feb. 10, 2012). 
